PURPOSE The evaluation of the short-term effect of topically applied coenzyme Q10 (CoQ10) on retina and choroid in Alzheimer's disease (AD) was aimed in this study. METHODS Randomized controlled study included a total of 93 patients, 62 of whom with AD. Thirty (32.3%) AD patients received treatment (Group 1), 32 (34.4%) AD patients observed without treatment (Group 2), and Group 3 included 31 (33.3%) healthy controls (HC). Neurological and ophthalmological examinations including optical coherence tomography (OCT) were executed. RESULTS Retinal nerve fiber layer (RNFL) thickness in all quadrants increased following CoQ10 treatment in Group 1; however significant rise yielded in average and temporal quadrant RNFL thickness. Average and superonasal sector ganglion cell-inner plexiform layer (GCIPL) thickness increased significantly following CoQ10 treatment. The correlation analysis between difference in pre- and posttreatment OCT values in Group 1 revealed that rise in average RNFL thickness was inversely correlated with duration of the disease and rise in average GCIPL thickness and superonasal sector thickness was inversely correlated with severity of the disease. CONCLUSION Short-term topical CoQ10 resulted in improvement in AD related retinal ganglion cell (RGC) loss which may reflect the salvage of some RGCs in the reversible transitional phase. More bioavailability through intravitreal route of administration and longer duration of effect with sustained release forms may possibly help enhalting the RGC loss, especially incipience of neurodegenerative diseases.

中文翻译：

---

Q10：使用局部辅酶挽救阿尔茨海默氏病过渡期的视网膜神经节细胞Q10：可能吗？

目的本研究旨在评估局部应用辅酶Q10（CoQ10）对阿尔茨海默病（AD）视网膜和脉络膜的短期作用。方法随机对照研究共纳入93例患者，其中62例患有AD。30名（32.3％）AD患者接受了治疗（第1组），有32名（34.4％）未经治疗的AD患者（第2组），第3组包括31名（33.3％）健康对照（HC）。进行了神经科和眼科检查，包括光学相干断层扫描（OCT）。结果在第1组进行CoQ10治疗后，所有象限的视网膜神经纤维层（RNFL）厚度增加；但是，平均和时间象限RNFL厚度显着上升。辅酶Q10处理后，平均和上鼻窦神经节细胞内丛状层（GCIPL）厚度显着增加。第1组治疗前和治疗后OCT值差异之间的相关性分析表明，平均RNFL厚度的增加与疾病的持续时间成反比，而平均GCIPL厚度和上鼻窦的厚度的增加与疾病的严重程度成反比。结论短期局部用辅酶Q10可以改善AD相关的视网膜神经节细胞（RGC）丢失，这可能反映了某些RGC在可逆过渡期中的挽救作用。通过玻璃体内给药途径获得更大的生物利用度以及持续释放形式的更长作用持续时间可能有助于减少RGC的损失，尤其是神经退行性疾病的发作。